A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Clinical trial NCT06684847 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06684847
Sponsor: argenx
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Sjogrens Disease

Start date: 2025-01-15
Primary completion: 2027-07-01
Enrollment: 631

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.